Fetal Fentanyl Syndrome: Unveiling a New Syndrome Linked to Fentanyl Use During Pregnancy
Dr. Karen Gripp, MD, Chief of the Division of Medical Genetics at Nemours Children’s Health in Wilmington, has been at…
FDNA
Mar 15, 2017, 03:00 ET
Boston, MA (PRWEB) March 15, 2017 — “FDNA launched the Year of Discovery on February 28th, 2017 to unite clinicians, labs and patients for rare disease advancements. March, the first month of the initiative, spotlights developmental syndromes classified as RASopathies, with support from Blueprint Genetics, a genetic knowledge company using Next-Generation Sequencing for clinical genetic diagnostics.
Clinicians and patients are encouraged to get involved to help advance understanding of syndromes in this category. As an incentive to get involved, Blueprint Genetics will donate $1* to the Noonan Syndrome Foundation for every case uploaded in March to FDNA’s free application designed for healthcare professionals, Face2Gene. The Noonan Syndrome Foundation seeks to support, educate, and advocate for those with a RASopathy condition known as Noonan Syndrome.”
Dr. Karen Gripp, MD, Chief of the Division of Medical Genetics at Nemours Children’s Health in Wilmington, has been at…
Dr Giulia Pascolini, an esteemed Italian M.D. and Ph.D., is currently responsible for the Genetic Counselling Service of the Istituto…
Founded in 2017, the Spanish Coffin Siris Syndrome Association is an organization dedicated to supporting families affected by this rare…